par Di Leo, Angelo 
;Desmedt, Christine ;Bartlett, John M S;Piette, Fanny;Ejlertsen, Bent;Pritchard, Kathleen;Larsimont, Denis ;Poole, Christopher;Isola, Jorma;Earl, Helena;Mouridsen, Henning;O'Malley, Frances P;Cardoso, Fatima ;Tanner, Minna;Munro, Alison;Twelves, Chris J;Sotiriou, Christos ;Shepherd, Lois;Cameron, David A;Piccart-Gebhart, Martine ;Buyse, Marc;HER2/TOP2A Meta-analysis Study Group,
Référence Lancet oncology, 12, 12, page (1134-1142)
Publication Publié, 2011-11
;Desmedt, Christine ;Bartlett, John M S;Piette, Fanny;Ejlertsen, Bent;Pritchard, Kathleen;Larsimont, Denis ;Poole, Christopher;Isola, Jorma;Earl, Helena;Mouridsen, Henning;O'Malley, Frances P;Cardoso, Fatima ;Tanner, Minna;Munro, Alison;Twelves, Chris J;Sotiriou, Christos ;Shepherd, Lois;Cameron, David A;Piccart-Gebhart, Martine ;Buyse, Marc;HER2/TOP2A Meta-analysis Study Group, Référence Lancet oncology, 12, 12, page (1134-1142)
Publication Publié, 2011-11
Article révisé par les pairs
| Titre: |
|
| Auteur: | Di Leo, Angelo; Desmedt, Christine; Bartlett, John M S; Piette, Fanny; Ejlertsen, Bent; Pritchard, Kathleen; Larsimont, Denis; Poole, Christopher; Isola, Jorma; Earl, Helena; Mouridsen, Henning; O'Malley, Frances P; Cardoso, Fatima; Tanner, Minna; Munro, Alison; Twelves, Chris J; Sotiriou, Christos; Shepherd, Lois; Cameron, David A; Piccart-Gebhart, Martine; Buyse, Marc; HER2/TOP2A Meta-analysis Study Group, |
| Informations sur la publication: | Lancet oncology, 12, 12, page (1134-1142) |
| Statut de publication: | Publié, 2011-11 |
| Sujet CREF: | Cancérologie |
| MeSH keywords: | Anthracyclines -- administration & dosage |
| Antigens, Neoplasm -- genetics | |
| Antineoplastic Combined Chemotherapy Protocols -- therapeutic use | |
| Breast Neoplasms -- drug therapy -- genetics -- mortality -- pathology | |
| Chemotherapy, Adjuvant | |
| Chi-Square Distribution | |
| Clinical Trials, Phase III as Topic | |
| DNA Topoisomerases, Type II -- genetics | |
| DNA-Binding Proteins -- genetics | |
| Disease-Free Survival | |
| Evidence-Based Medicine | |
| Female | |
| Gene Amplification | |
| Gene Deletion | |
| Humans | |
| In Situ Hybridization, Fluorescence | |
| Individualized Medicine | |
| Kaplan-Meier Estimate | |
| Middle Aged | |
| Patient Selection | |
| Predictive Value of Tests | |
| Proportional Hazards Models | |
| Randomized Controlled Trials as Topic | |
| Receptor, erbB-2 -- genetics | |
| Risk Assessment | |
| Risk Factors | |
| Survival Rate | |
| Time Factors | |
| Treatment Outcome | |
| Tumor Markers, Biological -- genetics | |
| Note générale: | Journal Article |
| Meta-Analysis | |
| Research Support, Non-U.S. Gov't | |
| SCOPUS: ar.j | |
| Langue: | Anglais |
| Identificateurs: | urn:issn:1470-2045 |
| info:doi/10.1016/S1470-2045(11)70231-5 | |
| info:pii/S1470-2045(11)70231-5 | |
| info:scp/81255129146 | |
| info:pmid/21917518 |
